Insider trade

Officer sold ~$2.21M of JAZZ shares in the open market

Traded Feb 26, 2026 · Filed Mar 3, 2026

Why it stands out

Jazz Pharmaceuticals's & Chief Legal Officer sold $2.21M of Jazz Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,209,481

Shares × reported transaction price

Timing vs results

2 days after results of Feb 24, 2026, 68 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.4%	−0.5%	+0.1%
30 days	+0.1%	−3.6%	+3.8%
90 days	+24.6%	+11.5%	+13.1%
180 days	+34.3%	+12.8%	+21.5%

Past results only. Not a forecast.

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.